For the estimated 140 million adults in China living with type 2 diabetes, selecting an effective, tolerable, and sustainable glucose-lowering therapy is critical—not only for glycemic control but also for long-term adherence and quality of life. In June 2024, a novel oral antihyperglycemic agent—caoglitinib tablets—received regulatory approval in China as the country’s first domestically developed biweekly DPP-4 inhibitor, offering a distinctive therapeutic option in the evolving landscape of diabetes management.
Caoglitinib is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in adults with type 2 diabetes mellitus. It may be used as monotherapy or in combination with metformin. Its mechanism of action centers on reversible inhibition of DPP-4 enzyme activity, thereby increasing endogenous concentrations of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This results in glucose-dependent stimulation of insulin secretion from pancreatic beta cells and suppression of glucagon release from alpha cells—leading to clinically meaningful reductions in both fasting and postprandial plasma glucose levels without significantly increasing hypoglycemia risk.
As with other DPP-4 inhibitors, caoglitinib is contraindicated in patients with type 1 diabetes mellitus or diabetic ketoacidosis. It is also not recommended for individuals with known hypersensitivity to caoglitinib or any of its excipients. Use during pregnancy and lactation should be approached with caution; clinicians must weigh potential benefits against theoretical risks following thorough individualized assessment.
A defining pharmacokinetic feature of caoglitinib is its exceptionally prolonged half-life—approximately 131.5 hours—enabling a unique dosing regimen: 10 mg (two tablets) administered once every 14 days. This biweekly schedule translates to just 26 doses per year, markedly reducing treatment burden compared with daily oral agents. Clinical evidence suggests this extended-interval dosing improves adherence by minimizing missed doses—a key contributor to suboptimal glycemic outcomes in real-world practice.
To further support treatment continuity and patient convenience, the manufacturer has introduced an 8-tablet packaging format. Designed to cover two months of therapy (two doses per month), this configuration reduces the frequency of pharmacy visits and mitigates the risk of treatment interruption due to medication stockouts or prescription lapses.
While caoglitinib represents a meaningful advance in simplifying pharmacologic management for select individuals with type 2 diabetes, it is essential to emphasize that pharmacotherapy remains one component of comprehensive care. Lifestyle interventions—including medical nutrition therapy, regular physical activity, weight management where appropriate, and ongoing diabetes self-management education—remain foundational. Clinicians should integrate caoglitinib into personalized treatment plans only after careful consideration of comorbidities, renal function, concomitant medications, and patient preferences—always reinforcing that optimal diabetes control hinges on synergy between pharmacologic and nonpharmacologic strategies.